Women with endometriosis who were prescribed medical cannabis reported less pain and better sleep over two years, according to a new observational study using UK data. The researchers stress the results do not prove that cannabis was responsible, as first reported by Cannabis Health.
The study followed 101 women prescribed cannabis-based medicines and recorded in the UK Medical Cannabis Registry. It was published in the Australian and New Zealand Journal of Obstetrics and Gynaecology.
What the study found
Participants completed questionnaires before starting treatment and again after one, three, six, 12, 18 and 24 months. Improvements were seen in pain severity and in the impact of pain on daily life at every follow-up point. Sleep, anxiety and overall quality of life also improved and the gains were sustained across the two years.
The study also looked at opioid use. Average prescribed opioid use fell from the equivalent of 19.9mg of morphine a day at the start to 14.8mg after two years. Of the 46 participants prescribed opioids at some point, 12 (about 26%) had what the researchers judged a clinically meaningful reduction by 24 months.
At the start, 33 patients were prescribed oil alone, 60 were given dried flower alongside oil and eight received flower alone.
Eighteen of the 101 patients reported a total of 165 adverse events, around half of which the researchers classed as mild. The most commonly reported were fatigue, lethargy and headaches.
Limits of the research
The authors said the findings cannot show that medical cannabis caused the improvements. The study was observational with no control group, so other factors could have influenced the results, and patients were given different products and doses.
They noted that no randomised controlled trials have specifically examined cannabis-based medicines for endometriosis-associated pain, and called for further trials to establish effectiveness and safety.
Endometriosis affects around one in ten women of reproductive age. Tissue similar to the lining of the womb grows elsewhere in the body, which can cause severe pain, inflammation and, in some cases, fertility problems.
Wider evidence
The results follow a 2024 survey led by Victoria Jasinski and colleagues at Charité University Medicine Berlin, published in Archives of Gynecology and Obstetrics. It questioned 912 people with endometriosis in Germany, Austria and Switzerland. Of 114 respondents who used cannabis, many rated it the most effective self-management strategy studied, and 91% reported better sleep, 90% improved menstrual pain and 80% improved non-cyclical pelvic pain.
Much of the existing evidence relies on surveys and observational research. A randomised trial is under way in Scotland. The ENDOCAN Phase 2 trial, led by Dr Lucy Whitaker with Professors Andrew Horne and Philippa Saunders at the University of Edinburgh, is testing Ananda Pharma’s MRX1 CBD oral solution in up to 100 women with endometriosis-associated pain.
The Chief Scientist Office-funded study is running across NHS Lothian and NHS Grampian. It is double-blind and placebo-controlled, with participants randomly assigned to MRX1 or a placebo for 12 weeks.
Specialist doctors in the UK have been able to prescribe cannabis-based medicines since 1 November 2018, although NHS prescriptions remain rare and most patients use private clinics.

Join the conversation
Be the first to have your say.
Has medical cannabis helped with pain or sleep for you or someone you know? How did it go?